February 14, 2018 / 11:24 PM / 2 months ago

BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector

Feb 14 (Reuters) - Amag Pharmaceuticals Inc:

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN

* AMAG PHARMACEUTICALS - EXPECTS TO FILE A NEW DRUG APPLICATION THIS QUARTER FOR A NEW CHEMICAL ENTITY (BREMELANOTIDE) ​

* AMAG PHARMACEUTICALS INC - ‍EXPECTS SUBCUTANEOUS AUTO-INJECTOR TO BE AVAILABLE IN SECOND HALF OF MARCH​

* AMAG PHARMACEUTICALS INC - WILL CONTINUE TO OFFER IM FORMULATION OF MAKENA IN BOTH SINGLE-DOSE AND MULTI-DOSE VIALS​

* AMAG PHARMACEUTICALS INC - ‍MAKEN’S 7-YEAR ORPHAN DRUG EXCLUSIVITY EXPIRED EARLIER THIS MONTH​

* AMAG PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF MAKENA (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR ‍​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below